[{"id":"535e2033-262c-4d9e-9ba9-7faa44eefd1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03332121","created_at":"2021-01-18T16:27:15.870Z","updated_at":"2024-07-02T16:36:20.724Z","phase":"Phase 1","brief_title":"B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma","source_id_and_acronym":"NCT03332121","lead_sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e B001"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/22/2018","start_date":" 03/22/2018","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 02/28/2021","study_completion_date":" 02/28/2021","last_update_posted":"2021-11-15"}]